Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

Next Previous
X
Search
Trial Profile

HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms HELP Study
  • Sponsors Dyax; Shire

    • Most Recent Events

    • 28 Mar 2022 According to a Takeda Pharma media release, the company has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO TAKHZYRO (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older in Japan, based on data from HELP, HELP Study Open-label Extension (OLE) and NCT04180163.
    • 28 Feb 2022 Results of this post-hoc analysis from two studies HELP (NCT02586805) and HELP OLE (NCT02741596) presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 28 Feb 2022 Post-hoc analysis of HELP and HELP OLE published in Takeda Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top